<p>The US government on Saturday stopped a Baltimore manufacturing plant that ruined 15 million doses of Johnson & Johnson's Covid-19 vaccine from making the vaccine developed by AstraZeneca Plc, <em>The New York Times</em> reported.</p>.<p>J&J said in a statement that it was "assuming full responsibility regarding the manufacturing of drug substance for its Covid-19 vaccine at the Emergent BioSolutions Inc. Bayview facility."</p>.<p><strong>Read | </strong><a href="https://www.deccanherald.com/international/five-things-to-know-about-the-astrazeneca/oxford-covid-19-vaccine-969925.html" target="_blank"><strong>Five things to know about the AstraZeneca/Oxford Covid-19 vaccine</strong></a></p>.<p>It did not specify if it will take over the plant. The company did not respond to Reuters' requests for comment for clarification.</p>.<p><em>The New York Times</em> reported that AstraZeneca said in a statement it will work with President Joe Biden's administration to find an alternative site. The drugmaker did not respond to a request for comment.</p>.<p><a href="https://www.deccanherald.com/tag/coronavirus" target="_blank"><strong>CORONAVIRUS SPECIAL COVERAGE ONLY ON DH</strong></a></p>.<p>The move by the US Department of Health and Human Services' will render the Emergent BioSolutions facility solely devoted to making the Johnson & Johnson single-dose vaccine and is meant to avoid future mix-ups, according to the newspaper report, which cites two senior federal health official</p>.<p>The US government's top infectious disease doctor told Reuters the country may not need AstraZeneca's vaccine, even if it wins approval.</p>
<p>The US government on Saturday stopped a Baltimore manufacturing plant that ruined 15 million doses of Johnson & Johnson's Covid-19 vaccine from making the vaccine developed by AstraZeneca Plc, <em>The New York Times</em> reported.</p>.<p>J&J said in a statement that it was "assuming full responsibility regarding the manufacturing of drug substance for its Covid-19 vaccine at the Emergent BioSolutions Inc. Bayview facility."</p>.<p><strong>Read | </strong><a href="https://www.deccanherald.com/international/five-things-to-know-about-the-astrazeneca/oxford-covid-19-vaccine-969925.html" target="_blank"><strong>Five things to know about the AstraZeneca/Oxford Covid-19 vaccine</strong></a></p>.<p>It did not specify if it will take over the plant. The company did not respond to Reuters' requests for comment for clarification.</p>.<p><em>The New York Times</em> reported that AstraZeneca said in a statement it will work with President Joe Biden's administration to find an alternative site. The drugmaker did not respond to a request for comment.</p>.<p><a href="https://www.deccanherald.com/tag/coronavirus" target="_blank"><strong>CORONAVIRUS SPECIAL COVERAGE ONLY ON DH</strong></a></p>.<p>The move by the US Department of Health and Human Services' will render the Emergent BioSolutions facility solely devoted to making the Johnson & Johnson single-dose vaccine and is meant to avoid future mix-ups, according to the newspaper report, which cites two senior federal health official</p>.<p>The US government's top infectious disease doctor told Reuters the country may not need AstraZeneca's vaccine, even if it wins approval.</p>